



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



MRTX-1719
Item No. 36563

CAS Registry No.: 2630904-45-7
Formal Name: (2R)-2-[4-[4-(aminomethyl)-1,2-dihydro-1-oxo-6-phthalaziny]-1-methyl-1H-pyrazol-5-yl]-4-chloro-6-(cyclopropyloxy)-3-fluoro-benzonitrile (M)-27
Synonym:
MF: C₂₃H₁₈ClFN₆O₂
FW: 464.9
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MRTX-1719 is supplied as a solid. A stock solution may be made by dissolving the MRTX-1719 in the solvent of choice, which should be purged with an inert gas. MRTX-1719 is soluble in DMSO and acetonitrile.

Description

MRTX-1719 is an inhibitor of the protein arginine methyltransferase 5 (PRMT5) and methylthioadenosine (MTA) complex.¹ It selectively binds to the PRMT5/MTA complex over the PRMT5 and S-adenosyl-L-methionine (SAM) complex (K_d s = 0.14 and 9.4 pM, respectively). MRTX-1719 selectively decreases protein dimethylarginine methylation levels in *MTAP*^{-/-} HCT116 colon cancer cells, which lack methylthioadenosine phosphorylase (MTAP; IC₅₀ = 8 nM), over wild-type HCT116 cells (IC₅₀ = 653 nM), as well as selectively reduces the viability of *MTAP*^{-/-} HCT116 cells (IC₅₀ = 12 nM) over wild-type HCT116 cells (IC₅₀ = 890 nM). *In vivo*, MRTX-1719 (12.5-100 mg/kg per day) reduces tumor volume in an *MTAP*^{-/-} Lu-99 lung cancer mouse xenograft model.

Reference

1. Smith, C.R., Aranda, R., Bobinski, T.P., *et al.* Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5•MTA complex for the treatment of *MTAP*-deleted cancers. *J. Med. Chem.* **65**(3), 1749-1766 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/26/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM